News and Updates
Announcement of €4.1 million funding raise
March 2026
With a little help from Sky News, we’re excited to announce that Ternary Therapeutics has raised €4.1m (£3.6m). The round was led by daphni, with participation from Pace Ventures, the i&i Biotech Fund, and UK Innovation & Science Seed Fund [UKI2S], managed by Future Planet Capital.
This investment enables us to scale our AI-driven platform to discover molecular glue therapeutics. By combining physics-informed AI with rapid experimental validation, we are turning what has historically been a chance discovery process into a repeatable engineering system for drug discovery.
As part of its next phase, we have appointed Dr Ian Taylor to our Board. Dr Taylor is a veteran of targeted protein degradation research and recently was CSO and President of R&D at Arvinas.
Read in: Sky News, Business Journal, Startup Rise, Cambridge Biocapital, Soapbox VC
Hiring two positions for the drug discovery team
September 2025
We are hiring two new positions within the drug discovery team!
In-vitro, lab-based biologist - Stevenage Biosciences Catalyst
Synthetic medicinal chemist (desk-based) - London
Any questions, please contact Adam Yip - a.yip@ternarytx.co.uk
NB: These positions have now been filled.
Preprint published comparing FEP and Boltz-2 for molecular glue optimisation
September 2025
This study presents the first comprehensive comparison of two computational methods for predicting their binding affinity: the accurate-but-costly Free Energy Perturbation (FEP) and the fast co-folding model Boltz-2. Across 140 measurements on six complexes, FEP consistently demonstrated strong predictive accuracy. We also demonstrate ability of FEP to predict selectivity between off-targets.
Link to Paper: https://doi.org/10.26434/chemrxiv-2025-tb29n
Hiring a new CADD scientist for the tech platform team
July 2025
We are expanding our tech platform team at TernaryTx by hiring a Senior Computational Chemist based in London, UK!
We are looking for people with experience in Python and handling protein structures.
The deadline to apply is the 11th August. Please reach out to Dominykas Lukauskis if you want to learn more about the role. NB: This position has now been filled.
Lab opening at the Stevenage Biosciences Catalyst
March 2025
We are thrilled to establish our wet-lab at the Stevenage Bioscience Catalyst, an ideal environment for a startup, and have been so impressed with the facilities and support from the SBC team. A big thank you to Jackie Hunter for making the connection, and to Marco Delise and Ela Nowak for their warm welcome and for helping us get set up.
Coming out of stealth - Press release
March 2025
On March 3, 2025, London-based biotech startup TernaryTx announced the launch of its revolutionary AI-driven platform for designing "molecular glue" therapeutics to target previously "undruggable" proteins. Backed by European venture funds Pace Ventures and I&I Bio, their proprietary suite of tools (Leopard, Puffin, Gecko, and Octopus) uses artificial intelligence and molecular dynamics to accelerate the discovery of novel drugs with greater accuracy and reduced costs. The platform has already demonstrated promising early results in identifying molecular glues for high-value targets in inflammatory and metabolic diseases, marking a significant potential breakthrough in the pharmaceutical industry.
Link to press release: LinkedIn Post